Diadema Partners LP Apellis Pharmaceuticals, Inc. Transaction History
Diadema Partners LP
- $233 Billion
- Q4 2024
A detailed history of Diadema Partners LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 100,000 shares of APLS stock, worth $2.43 Million. This represents 1.37% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$2.43 Million% of portfolio
1.37%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
301Shares Held
111MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$297 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$289 Million17.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$244 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$234 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$141 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.67B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...